Highest-materiality recent filing
Envista CEO Paul Keel named Chairman; gets $10M equity award, salary bump
Paul Keel appointed Chairman of Board effective Aug 19, 2026; Scott Huennekens becomes Lead Independent Director.
Envista Q2 core sales +5%, adj. EPS $0.41 (+58% YoY); raises FY guidance
Sales $731M, core sales growth 5.0% YoY; GAAP net income $54M vs $26M in Q2 2025.
Envista CAO Faez Kaabi to retire Aug 6, 2026; Coree Thomas appointed successor
Faez Kaabi notified resignation as CAO and principal accounting officer effective Aug 6, 2026, due to retirement.
Stockholders elected all eight director nominees: votes for ranged from 145,760,570 to 149,459,395.
Envista Q1 2026: core sales +9.5%, adjusted EPS $0.36 (+50% YoY), new $300M buyback
Revenue $706M, core sales growth 9.5% YoY; Specialty Products +8.4%, Equipment & Consumables +11.5%.
Envista Q4 2025: core revenue +10.8%, adj. EPS $0.38 (+58% YoY); FY 2026 guidance issued
Q4 2025 revenue $751M; core sales +10.8% YoY; GAAP EPS $0.20; adjusted EPS $0.38 (+58%).
Envista releases 2024 Sustainability Report; $1.9M donated, safety incident rate down 13%
Donated $1.9M in goods/services via Envista Smile Project to expand oral care access for underserved communities.
Q3 sales $670M, core sales growth 9.4% YoY; all major businesses positive growth.
Director Barbara B. Hulit resigns from Envista board effective Sept 26, 2025
Barbara B. Hulit submitted her resignation from the Board on September 15, 2025.
Envista Q2 revenue $682M (+5.6% core); raises FY adjusted EPS guidance to $1.05-$1.15
Q2 net income $26M vs loss of $1,152M a year ago; adjusted EPS $0.26 (+136% YoY).
Envista appoints Stryker executive J. Andrew Pierce to Board, adds Audit Committee role
J. Andrew Pierce elected to Board effective July 14, 2025, expanding Board from 8 to 9 members.
Envist stockholders approve all four proposals at 2025 annual meeting
All eight director nominees elected with >99% support for most.
Envista Q1 sales $617M, adj. EPS $0.24, maintains 2025 guidance
Sales $617M, core sales +0.2% YoY; net income $18M, adjusted net income $42M.
Envista Q4 net income $1M, core sales +2%; FY2025 adj EPS guide $0.95-$1.05
Q4 net income $1M vs loss of $217M a year ago; adjusted diluted EPS $0.24 vs $0.29.
Envista authorizes $250M share repurchase program through Dec 31, 2026
Board authorized repurchase of up to $250 million in common stock.
Envista releases 2023 Sustainability Report with 26% reduction in Scope 1 GHG emissions
Absolute Scope 1 GHG emissions decreased 26% year-over-year; total (Scope 1+2) intensity down 3.5%.
Envista Q3: net income $8.2M ($0.05 EPS), core sales down 5.3%, adj EBITDA $54.9M
GAAP net income $8.2M ($0.05 diluted EPS) vs $21.5M ($0.12) in Q3 2023.
Envista Q2 net loss $1.15B on $1.15B goodwill impairment; guides FY core sales down 1-4%
Net loss $1,151.6M ($6.69 per share) includes $1,153.8M non-cash goodwill and intangible impairment.
Eric Hammes appointed CFO effective August 8, 2024; interim CFO Stephen Keller returns to lead investor relations.
Envista's SVP & President of Orthodontics Eric Conley steps down effective June 3
Eric Conley notified Envista on May 27, 2024, that he will step down as SVP and President, Orthodontics.
Envista annual meeting results: officer exculpation approved, Paul Keel elected director
Charter amendment to exculpate officers approved: 130.7M for, 27.6M against, effective May 21, 2024.
Envista Q1 net income $23.6M, adjusted EPS $0.26 (down 32% YoY); Paul Keel appointed CEO
Reported sales $623.6M, core sales up 0.4% YoY.
Envista appoints Paul Keel as CEO effective May 1, 2024; succeeds Amir Aghdaei
Paul Keel, former CEO of Smiths Group plc, named President & CEO and board member effective May 1, 2024.
Envista director Barbara Hulit terminates consulting agreement, effective Apr 30, 2024
Consulting agreement with director Barbara Hulit signed Jan 2, 2024, for 180-day term.
Envista announces planned CEO succession; Aghdaei to step down once successor appointed
CEO Amir Aghdaei to step down upon appointment of successor; board formed search committee for external candidates.
Envista Q4 net loss $217.4M on $258.3M impairment; adjusted EPS $0.29; guides FY2024 margin 16-17%
Q4 reported sales $645.6M, core sales down 2.0% YoY; net loss of $1.27 diluted EPS includes $258.3M goodwill/intangibles impairment.
Envista names three new executives; Nobel Biocare president exits Dec 31
Patrik Eriksson, SVP and President of Nobel Biocare, departs effective Dec 31, 2023.
Envista releases 2022 Sustainability Report; highlights 20% GHG reduction
Scope 1 and 2 GHG emissions down 20% absolute, 22% intensity YoY.
Envista Q3 adj EPS $0.43, revises FY core sales outlook to slightly down
Reported sales $631.3M, core sales up 0.8% YoY.
Envista refinances with $530M USD and €350M EUR term loans; revolver $750M thru Aug 2028
Second amended credit agreement signed Aug 31, 2023; matures Aug 31, 2028 with springing maturity tied to convertible notes.
Envista issues $500M 1.75% convertible notes due 2028, exchanges $401M existing notes
Issued $500.25M in 1.75% Convertible Senior Notes due August 2028; initial conversion rate 21.5942 shares per $1,000 principal (~$46.31/share).
Envista prices $435M 1.75% convertible notes due 2028; concurrent exchange of 2025 notes
$435M principal of 1.75% convertible notes due 2028 priced; underwriters option for additional $65.25M.
Envista announces $435M convertible notes offering, concurrent exchange of 2025 notes
$435M principal of Convertible Senior Notes due 2028; initial purchasers option for additional $65.25M.
Envista Q2 revenue up 2.6% to $662.4M; adjusted EPS $0.43 vs $0.48 YoY
Reported sales $662.4M (+2.6% YoY); core sales +2.1%.
Envista CFO Howard Yu to step down Sept 22; interim CFO and CAO appointed
Howard Yu resigns as SVP & CFO effective Sept 22, 2023, to join another company; no disagreement with Envista.
Envista SVP Kyrillos departs; severance package totals $1.096M
Jean-Claude Kyrillos, SVP & President of Diagnostics and Digital Solutions, left effective June 30, 2023, as previously announced.
NVST annual meeting results: directors elected, EY ratified, say-on-pay approved; bylaws amended
Stockholders elected directors: Aghdaei, Gallahue, Hulit, Jain, Raskas (lowest votes for Raskas: 88M for vs 67M withheld).
Envista Q1 sales down 0.7% to $627.2M; adjusted EPS $0.38 vs $0.47 YoY
Reported sales $627.2M (-0.7%); core sales declined 2.4% YoY.
Envista SVP and President of Diagnostics & Digital Solutions to depart June 30, 2023
Jean-Claude Kyrillos, SVP and President of Diagnostics and Digital Solutions, mutually agreed to terminate employment effective June 30, 2023.
Envista Q4 adjusted EPS $0.52 beats $0.46; guides 2023 low-single-digit core growth
Q4 reported sales $660.8M (+1.4% reported; +2.3% core).
Q3 reported sales $631.1M, core growth 4.9% YoY.
Envista releases 2021 Sustainability Report highlighting ESG progress
Achieved 99% gender pay equity and 99% ethnic pay equity in the U.S.
Sales $645.8M (+1.3% YoY), core sales growth 4.0%; net income $44.5M ($0.25 diluted EPS).
Directors Amir Aghdaei, Vivek Jain, Daniel A. Raskas elected with >150M votes each.
Envista to acquire Osteogenics Biomedical for ~$30M annual sales; closes Q3
Definitive agreement to acquire Osteogenics Biomedical, Allotech, OBI Biologics (Cytoplast brand).
Envista Q1 sales $631.4M, core growth 5.4%, completes IOS acquisition
Q1 sales $631.4M (+3.1% as-reported, +5.4% core growth YoY).
Total consideration of $582.5 million for certain assets, liabilities, and equity of Carestream subsidiaries.
Envista CAO resigns; CFO assumes accounting officer role
Kari-Lyn Moore resigns as Chief Accounting Officer effective April 22, 2022.
Envista Q4 sales up 5.8% to $651.8M; guides FY22 core growth 6-8%, adj EBITDA margin >20%
Q4 net income $42.5M ($0.24 diluted EPS); adjusted EPS $0.46 vs $0.43 in Q4 2020.
Envista closes divestiture of KaVo Treatment Unit & Instrument business for $383M total proceeds
Received $317.3M cash at closing; expects total gross proceeds of $383M including $30M earnout and $36.2M adjustments.
the Company’s Board of Directors’ appointment of Paul Keel, the Company’s President and Chief Executive Officer, to the role of Chairman of the Board, effective immediately.
Faez Kaabi notified Envista Holdings Corporation (the “Company”) of his intention to resign as Chief Accounting Officer and principal accounting officer of the Company effective as of August 6, 2026.
On June 2, 2026, the Company appointed Coree Thomas, the Company’s Vice President, Global Controller, as the Company’s Vice President and Chief Accounting Officer.
On July 15, 2024, Envista Holdings Corporation (the “Company”) announced that it has appointed Eric Hammes as the Senior Vice President and Chief Financial Officer of the Company, with such appointment to be effective as of August 8, 2024.
On April 15, 2024, Envista Holdings Corporation (the “Company”) announced that it has appointed Paul Keel as the President and Chief Executive Officer of the Company, with such appointment to be effective as of May 1, 2024
On February 22, 2024, Envista Holdings Corporation (the “Company”) and Amir Aghdaei, the President and Chief Executive Officer of the Company, entered into a transition letter agreement (the “Transition Agreement”), setting forth the terms of Mr. Aghdaei’s anticipated transition from his position as the Company’s President and Chief Executive Officer.
On December 11, 2023, Envista Holdings Corporation (the “Company”) and Patrik Eriksson, the Company’s SVP and President, Nobel Biocare, mutually agreed that Mr. Eriksson’s employment will terminate effective December 31, 2023.
On July 24, 2023, the Company appointed Stephen Keller, the Company’s Vice President, Investor Relations, as the Company’s interim principal financial officer, effective upon Mr. Yu’s departure.
On July 24, 2023, the Company appointed Faez Kaabi, the Company’s Vice President, Corporate Controller, as the Company’s Vice President and Chief Accounting Officer.
On July 20, 2023, Howard Yu notified Envista Holdings Corporation (the “Company”) that he will step down as Senior Vice President and Chief Financial Officer of the Company (in which capacities he serves as the Company’s principal financial and accounting officer), effective September 22, 2023 to join another company.
the Company and Jean-Claude Kyrillos, the Company’s SVP and President, Diagnostics and Digital Solutions, mutually agreed that Mr. Kyrillos’s employment would terminate effective June 30, 2023.
On April 11, 2023, Envista Holdings Corporation (the “Company”) and Jean-Claude Kyrillos, the Company’s SVP and President, Diagnostics and Digital Solutions, mutually agreed that Mr. Kyrillos’ employment will terminate effective June 30, 2023.
Max materiality 0.85 · Median 0.60 · Most common event earnings